SETD1B and breast cancer: Almost all patients with ASXL1 mutations showed acquisition of other additional genetic abnormalities during progression to BC (93.3%, 14 out of 15 cases), including mutations (12/15) in RUNX1 (4/15), TP53 (3/15), BCOR (2/15), and SETD1B (2/15) genes.